Cited by 152Drug Transport and Resistance MechanismsCannabis and Cannabinoid ResearchPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids

Open access

Holland, M L, Lau, D T T, Allen, J D, Arnold, J C·2007·British Journal of Pharmacology

DOI 10.1038/sj.bjp.0707467PMC PMC2190019

Open this paper in CoChat — free account Open PDF

Abstract

Background and purpose: Cannabinoids are used therapeutically for the palliation of the adverse side effects associated with cancer chemotherapy. However, cannabinoids also inhibit both the activity and expression of the multidrug transporter, P‐glycoprotein in vitro . Here we address the interaction of cannabinol (CBN), cannabidiol (CBD) and Δ 9 ‐tetrahydrocannabinol (THC) with the related multidrug transporter, ABCG2. Experimental approach: Cannabinoid inhibition of Abcg2/ABCG2 was assessed using flow cytometric analysis of substrate accumulation and ATPase activity assays. The cytotoxicity and chemosensitization by cannabinoids was determined with cell viability assays. Expression of cannabinoid and vanilloid receptors was assessed using reverse transcriptase polymerase chain reaction, and cannabinoid modulation of ABCG2 expression was examined using immunoblotting. Key results: CBN, CBD and THC increased the intracellular accumulation of the Abcg2/ABCG2 substrate, mitoxantrone, in an over‐expressing cell line. The THC metabolite, (−)‐11‐nor‐9‐carboxy‐Δ 9 ‐THC was much less potent. The plant cannabinoids inhibited both basal and substrate stimulated ATPase activity of human ABCG2. Cannabinoid cytotoxicity occurred in the absence of known cannabinoid cell surface receptors, and only at concentrations higher than those required for Abcg2/ABCG2 inhibition. Sub‐toxic concentrations of the cannabinoids resensitized the overexpressing cell line to the cytotoxic effect of Abcg2/ABCG2 substrates, mitoxantrone and topotecan. This occurred in the absence of any effect on ABCG2 expression. Conclusions and implications: Cannabinoids are novel Abcg2/ABCG2 inhibitors, reversing the Abcg2‐mediated multidrug‐resistant phenotype in vitro . This finding may have implications for the co‐administration of cannabinoids with pharmaceuticals that are ABCG2 substrates. British Journal of Pharmacology (2007) 152 , 815–824; doi: 10.1038/sj.bjp.0707467 ; published online 1 October 2007

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707467

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T. A., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,372
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1188 · Cited by 721
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 690
Self-citation
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 639
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase.
Sarkadi, B., Price, E. M., Boucher, R. C., Germann, U. A., & Scarborough, G. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42909-2 · Cited by 633
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610

Show all 38 references

Sorted by citations

Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 499
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
Stout, S. M., & Cimino, N. M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 350
Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomäus, R., Bernhardt, G., König, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 339
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis
Tomko, A. M., Whynot, E. G., Ellis, L. D., & Dupré, D. J. (2020) · Cancers · doi:10.3390/cancers12071985 · Cited by 241
Cannabinoids: Occurrence and Medicinal Chemistry
Appendino, G., Chianese, G., & Taglialatela‐Scafati, O. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940888 · Cited by 209
Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Wu, C., Ohnuma, S., & Ambudkar, S. V. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163887 · Cited by 172
Medicinal Cannabis—Potential Drug Interactions
Alsherbiny, M. A., & Li, C. G. (2018) · Medicines · doi:10.3390/medicines6010003 · Cited by 170
Cannabinoids as anticancer drugs: current status of preclinical research
Hinz, B., & Ramer, R. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01727-4 · Cited by 153
The Endocannabinoid System: A Target for Cancer Treatment
Laezza, C., Pagano, C., Navarra, G., Pastorino, O., Proto, M., Fiore, D., Piscopo, C., Gazzerro, P., & Bifulco, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030747 · Cited by 149
Anti‐tumour actions of cannabinoids
Hinz, B., & Ramer, R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14426 · Cited by 148
The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids
McAllister, S. D., Soroceanu, L., & Desprez, P. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9608-y · Cited by 144
The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?
Moreno, E., Cavic, M. R., Krivokuća, A., Casadó, V., & Canela, E. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00339 · Cited by 129
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
Tournier, N., Chevillard, L., Mégarbane, B., Pirnay, S., Scherrmann, J., & Declèves, X. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990848 · Cited by 125
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
Qian, Y., Gurley, B. J., & Markowitz, J. S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001089 · Cited by 123
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome
Anderson, L. L., Low, I. K., Banister, S. D., McGregor, I. S., & Arnold, J. C. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00600 · Cited by 121
Self-citation
Insights into the effects of the endocannabinoid system in cancer: a review
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., & Torres‐Suárez, A. I. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14331 · Cited by 114
Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines
Sultan, A., Marie, M. A., & Sheweita, S. A. (2018) · The Breast · doi:10.1016/j.breast.2018.06.009 · Cited by 113
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
Doohan, P. T., Oldfield, L., Arnold, J. C., & Anderson, L. L. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00616-7 · Cited by 107
Self-citation
Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1)
Holland, M. L., Allen, J. D., & Arnold, J. C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.079 · Cited by 99
Self-citation
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics
Cox, E. J., Maharao, N. V., Patilea-Vrana, G., Unadkat, J. D., Rettie, A. E., McCune, J. S., & Paine, M. F. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.001 · Cited by 91
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes
Chen, J., Borgelt, L. M., & Blackmer, A. B. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018822124 · Cited by 91
In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2)
zu Schwabedissen, H. E. M., & Kroemer, H. K. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_9 · Cited by 89
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators
Zattoni, I. F., Delabio, L. C., Dutra, J. D. P., Kita, D. H., Scheiffer, G., Hembecker, M., Pereira, G. D. S., Moure, V. R., & Valdameri, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114346 · Cited by 88
Targeting multidrug resistance in cancer by natural chemosensitizers
Hamed, A. R., Abdel‐Azim, N. S., Shams, K. A., & Hammouda, F. M. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0043-8 · Cited by 87
Cannabidiol-Δ 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity
Britch, S. C., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.046 · Cited by 83
Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Javid, F. A., Phillips, R. M., Afshinjavid, S., Verde, R., & Ligresti, A. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.010 · Cited by 82
Cannabinoids as Anticancer Drugs
Ramer, R., & Hinz, B. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.04.002 · Cited by 82
Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
“110 Preclinical studies have reported that cannabinoids may also bind membrane transporters including breast cancer resistance protein 111 and P-gp, 112,113 which can, theoretically, impact the effect of other medications.”
Background
Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study
Feinshtein, V., Erez, O., Ben‐Zvi, Z., Eshkoli, T., Sheizaf, B., Sheiner, E., & Holcberg, G. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.08.005 · Cited by 77
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy
Ramer, R., Schwarz, R., & Hinz, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00430 · Cited by 75
The Challenge of Exploiting ABCG2 in the Clinic
Robey, R. W., Ieranò, C., Zhan, Z., & Bates, S. E. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163913 · Cited by 73
Phytocannabinoid Pharmacology: Medicinal Properties of Cannabis sativa Constituents Aside from the “Big Two”
Sampson, P. B. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00965 · Cited by 79
Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
Feinshtein, V., Erez, O., Ben‐Zvi, Z., Erez, N., Eshkoli, T., Sheizaf, B., Sheiner, E., Huleihel, M., & Holcberg, G. (2013) · PeerJ · doi:10.7717/peerj.153 · Cited by 72
Neural correlates of interactions between cannabidiol and Δ 9 ‐tetrahydrocannabinol in mice: implications for medical cannabis
Todd, S. M., & Arnold, J. C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13333 · Cited by 72
Self-citation
Evaluation of Cell Cycle Arrest in Estrogen Responsive MCF-7 Breast Cancer Cells: Pitfalls of the MTS Assay
McGowan, E. M., Alling, N., Jackson, E., Yagoub, D., Haass, N. K., Allen, J. D., & Martiniello‐Wilks, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020623 · Cited by 73
Self-citation
ABCG2/BCRP: Specific and Nonspecific Modulators
Peña‐Solórzano, D., Stark, S., König, B., Sierra, C. A., & Ochoa‐Puentes, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21428 · Cited by 72
In Vitro and In Vivo Efficacy of Non-Psychoactive Cannabidiol in Neuroblastoma
Fisher, T., Golan, H., Schiby, G., Pri‐Chen, S., Smoum, R., Moshe, I., Peshes‐Yaloz, N., Castiel, A., Waldman, D., Gallily, R., et al. (2016) · Current Oncology · doi:10.3747/co.23.2893 · Cited by 69
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs
Chicoine, A. L., Illing, K., Vuong, S., Pinto, K. R., Alcorn, J., & Cosford, K. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.583404 · Cited by 68
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Franco, V., Bialer, M., & Perucca, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108442 · Cited by 70
Enhanced Brain Disposition and Effects of Δ9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout Mice
Spiro, A. S., Wong, A., Boucher, A. A., & Arnold, J. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035937 · Cited by 61
Self-citation
Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
Anderson, L. L., Etchart, M. G., Bahceci, D., Golembiewski, T. A., & Arnold, J. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-94212-6 · Cited by 59
Self-citation
Natural Products That Target Cancer Stem Cells.
Moselhy, J., Srinivasan, S., Ankem, M. K., & Damodaran, C. (2015) · PubMed · Cited by 57
Potential Pharmacokinetic Drug‐Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain
Vázquez, M., Guevara, N., Maldonado, C., Guidó, P. C., & Schaiquevich, P. S. (2020) · BioMed Research International · doi:10.1155/2020/3902740 · Cited by 59
The effects of dietary and herbal phytochemicals on drug transporters
Li, Y., Revalde, J. L., & Paxton, J. W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.004 · Cited by 56
Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer
Tomko, A. M., O’Leary, L. F., Trask, H., Achenbach, J. C., Hall, S. R., Goralski, K. B., Ellis, L. D., & Dupré, D. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01124 · Cited by 53
CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells
Arnold, J. C., Hone, P., Holland, M. L., & Allen, J. D. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70871-x · Cited by 50
Self-citation
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
Brzozowska, N., Li, K. M., Wang, X., Booth, J., Stuart, J. M., McGregor, I. S., & Arnold, J. C. (2016) · PeerJ · doi:10.7717/peerj.2081 · Cited by 49
Self-citation
Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
Olivas-Aguirre, M., Torres-López, L., Pottosin, I. I., & Dobrovinskaya, O. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617937 · Cited by 49
Prenatal THC Does Not Affect Female Mesolimbic Dopaminergic System in Preadolescent Rats
Traccis, F., Serra, V., Sagheddu, C., Congiu, M., Saba, P., Giua, G., Devoto, P., Frau, R., Cheer, J. F., & Melis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041666 · Cited by 48
Cannabinoid receptor ligands as potential anticancer agents – high hopes for new therapies?
Oesch, S., & Gertsch, J. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.07.0002 · Cited by 45
Delta9‐tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature
Fowler, C. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.84 · Cited by 44
The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Li, Y., Lu, J., & Paxton, J. W. (2012) · Current Drug Metabolism · doi:10.2174/1389200211209050624 · Cited by 44
The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia
Arnold, J. C., Boucher, A. A., & Karl, T. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884726 · Cited by 45
Self-citation
Oral delivery of cannabidiol: Revealing the formulation and absorption challenges
Šitovs, A., Logviss, K., Lauberte, L., & Mohylyuk, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105316 · Cited by 40
Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles
Fraguas‐Sánchez, A. I., Fernández-Carballido, A. M., Delié, F., Cohen, M., Martín‐Sabroso, C., Mezzanzanica, D., Figini, M., Satta, A., & Torres‐Suárez, A. I. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.07.008 · Cited by 40
Assessment of spent hemp biomass as a potential ingredient in ruminant diet: nutritional quality and effect on performance, meat and carcass quality, and hematological parameters in finishing lambs
Parker, N. B., Bionaz, M., Ford, H. R., Irawan, A., Trevisi, E., & Ateş, S. (2022) · Journal of Animal Science · doi:10.1093/jas/skac263 · Cited by 40
Cannabinoids and the placenta: Receptors, signaling and outcomes
Rokeby, A. C. E., Natale, B. V., & Natale, D. R. C. (2023) · Placenta · doi:10.1016/j.placenta.2023.03.002 · Cited by 42
Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway
Todd, S. M., Zhou, C., Clarke, D. J., Chohan, T. W., Bahceci, D., & Arnold, J. C. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.12.004 · Cited by 40
Self-citation
Maternal and Fetal Pharmacokinetic Analysis of Cannabidiol during Pregnancy in Mice
Ochiai, W., Kitaoka, S., Kawamura, T., Hatogai, J., Harada, S., Iizuka, M., Ariumi, M., Takano, S., Nagai, T., Sasatsu, M., et al. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000270 · Cited by 38
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
Buchtová, T., Lukáč, D., Škrott, Z., Chromá, K., Bártek, J., & Mistrík, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032885 · Cited by 38
A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors
Stefan, S. M., Jansson, P. J., Pahnke, J., & Namasivayam, V. (2022) · Scientific Data · doi:10.1038/s41597-022-01506-z · Cited by 37
Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks
Silveira, M. M., Arnold, J. C., Laviolette, S. R., Hillard, C. J., Celorrio, M., Aymerich, M. S., & Adams, W. K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.007 · Cited by 38
Self-citation
Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 34
Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis
Marzęda, P., Wróblewska-Łuczka, P., Drozd, M., Florek-Łuszczki, M., Załuska-Ogryzek, K., & Łuszczki, J. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126752 · Cited by 34
Therapeutic potential of cannabinoids in combination cancer therapy
Malhotra, P., Casari, I., & Falasca, M. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100774 · Cited by 33
Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol
Greene, N. Z., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5036-z · Cited by 31
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
Baker, D., Pryce, G., Jackson, S. J., Bolton, C., & Giovannoni, G. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.11.001 · Cited by 31
BCRP Inhibition: from Data Collection to Ligand‐Based Modeling
Montanari, F., & Ecker, G. F. (2014) · Molecular Informatics · doi:10.1002/minf.201400012 · Cited by 31
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions
Auzmendi, J., Palestro, P. H., Blachman, A., Gavernet, L., Merelli, A., Talevi, A., Calabrese, G. C., Ramos, A. J., & Lazarowski, A. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00032 · Cited by 31
Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment
Woerdenbag, H. J., Olinga, P., Kok, E. A., Brugman, D. A. P., van Ark, U. F., Ramcharan, A. S., Lebbink, P. W., Hoogwater, F. J. H., Knapen, D. G., de Groot, D. J. A., et al. (2023) · Cancers · doi:10.3390/cancers15072119 · Cited by 30
The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine
Skórzewska, M., & Gęca, K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01589-4 · Cited by 29
Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB 1 cannabinoid receptor agonists
Pryce, G., Visintin, C., Ramagopalan, S. V., Al‐Izki, S., Faveri, L. E. D., Nuamah, R. A., Mein, C. A., Montpetit, A., Hardcastle, A. J., Kooij, G., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-239442 · Cited by 29
A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies
Birer-Williams, C. M. C., Gufford, B. T., Chou, E., Alilio, M., VanAlstine, S., Morley, R. E., McCune, J. S., Paine, M. F., & Boyce, R. D. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000054 · Cited by 26
Anandamide down-regulates placental transporter expression through CB2 receptor-mediated inhibition of cAMP synthesis
Szilagyi, J. T., Wahler, G., Joseph, L. B., Wang, B., Rosen, T., Laskin, J. D., & Aleksunes, L. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.002 · Cited by 25
Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2)
Chen, X., Unadkat, J. D., & Mao, Q. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000505 · Cited by 22
Anti-cancer potential of cannabis terpenes in a Taxol-resistant model of breast cancer
Tomko, A. M., Whynot, E. G., O’Leary, L. F., & Dupré, D. J. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0792 · Cited by 20
Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer
Cherkasova, V., Kovalchuk, O., & Kovalchuk, I. (2021) · Cancers · doi:10.3390/cancers13174353 · Cited by 20
Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
Gharavi, R. B., Hedrich, W. D., Wang, H., & Hassan, H. E. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1711-5 · Cited by 19
Role of Cannabidiol for Improvement of the Quality of Life in Cancer Patients: Potential and Challenges
Green, R. J., Khalil, R., Mohapatra, S. S., & Mohapatra, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112956 · Cited by 19
New Insights into Antimetastatic and Antiangiogenic Effects of Cannabinoids
Ramer, R., & Hinz, B. (2014) · International review of cytology · doi:10.1016/bs.ircmb.2014.10.005 · Cited by 19
Cannabidiol's impact on drug-metabolization
Stöllberger, C., & Finsterer, J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.029 · Cited by 16
Effect of cannabinoids on the efficacy and side effects of anticancer therapeutic strategies – Current status of preclinical and clinical research
Ramer, R., & Hinz, B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108851 · Cited by 17
Emerging Roles of Endocannabinoids as Key Lipid Mediators for a Successful Pregnancy
Rava, A., & Trezza, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065220 · Cited by 16
Transcriptome Analysis of Cisplatin, Cannabidiol, and Intermittent Serum Starvation Alone and in Various Combinations on Colorectal Cancer Cells
Cherkasova, V., Ilnytskyy, Y., Kovalchuk, O., & Kovalchuk, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914743 · Cited by 15
Potential neonatal toxicity of new psychoactive substances
Fujiwara, R., Journey, M., Al‐Doori, F., Bell, P., Judge, B., Miracle, K., Ito, K., & Jones, S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108468 · Cited by 14
Sex‐specific susceptibility to psychotic‐like states provoked by prenatal THC exposure: Reversal by pregnenolone
Frau, R., & Melis, M. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13240 · Cited by 13
Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug–drug interactions of drugs of abuse
Wagmann, L., Maurer, H. H., & Meyer, M. R. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2276-y · Cited by 13
High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy
Czornyj, L. A., Guidó, P. C., Bramuglia, G. F., Rodiño, A., Feria-Romero, I. A., & Lazarowski, A. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.09.008 · Cited by 14
Phytocannabinoids as Chemotherapy Adjuncts—A Review for Users
Nahler, G. (2024) · Onco · doi:10.3390/onco4040021 · Cited by 12
In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function
Anderson, L. L., Etchart, M. G., MacNair, L., Land, M. H., Mosesova, I., Bonn‐Miller, M. O., & Arnold, J. C. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0053 · Cited by 12
Self-citation
Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence
Esmaeli, M., & Dehabadi, M. D. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03870-3 · Cited by 11
Oral Bioavailability and Disposition of Phytochemicals
Li, Y., & James, W. (2011) · InTech eBooks · doi:10.5772/26583 · Cited by 11
Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy
El‐Far, A. H., Elfadadny, A., Ragab, R. F., Hamada, R., Elbadawy, M., & Fu, J. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00208-x · Cited by 9
Targeting Colorectal Cancer: Unravelling the Transcriptomic Impact of Cisplatin and High-THC Cannabis Extract
Cherkasova, V., Ilnytskyy, Y., Kovalchuk, O., & Kovalchuk, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084439 · Cited by 9
Medicinal Cannabis: an overview for health-care providers
Wallach, J. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00005-2 · Cited by 9
11-Nor-9-carboxy-∆ 9 -tetrahydrocannabinol - a ubiquitous yet underresearched cannabinoid. A re- view of the literature
Ujváry, I., & Grotenhermen, F. (2014) · Cited by 9
Cannabis sativa: Cervical cancer treatment- Role of phytocannabinoids-A story of concern
Malabadi, R. B., Sadiya, M. R., Prathima, T. C., Kolkar, K. P., Mammadova, S. S., & CHALANNAVAR, R. K. (2024) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2024.17.2.0076 · Cited by 10

Authors: Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C.
Affiliations: The University of Sydney (AU)
Centenary Institute (AU)
Corresponding author: Arnold, J C
ORCID: Holland, M L
Arnold, J C
Venue: British Journal of Pharmacology
Publisher: Wiley
Published: 2007-11
Volume: 152
Issue: 5
Pages: 815-824
ISSN: 0007-1188 (ISSN-L)
1476-5381
DOI: 10.1038/sj.bjp.0707467
PMC: PMC2190019
OpenAlex: W1571533074
Cited by: 150
References: 38
Citations by year: 2026: 7 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 14 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 9 · 2017: 5 · 2016: 14 · 2015: 6 · 2014: 3 · 2013: 10 · 2012: 6
FWCI: 1.01
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 455 d)
Locations: British Journal of Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Health and Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: ABCG2, multidrug transporter, cannabinol, cannabidiol, delta-9-tetrahydrocannabinol, multidrug resistance, chemosensitization, mitoxantrone, topotecan, cannabinoid receptors, vanilloid receptor, drug-drug interactions
MeSH terms: ATP Binding Cassette Transporter, Subfamily G, Member 2, Adenosine Triphosphatases, Animals, Cannabinoids, Cell Line, Cell Survival, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Mitoxantrone, Neoplasm Proteins, Plant Extracts, Sulfasalazine, Dronabinol, Immunoblotting, ATP-Binding Cassette Transporters, Topotecan, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Cannabinoid, CB1, Cell Line, Tumor, TRPV Cation Channels, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks